This is a StreetInsider.com Premium Only Page

Johnson & Johnson (JNJ) – Company Press Releases

Apr 22, 2024 04:30 PM Johnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)

Apr 16, 2024 06:25 AM Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%

Apr 16, 2024 06:20 AM CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results

Apr 16, 2024 06:20 AM Johnson & Johnson Reports Q1 2024 Results

Apr 8, 2024 06:06 PM Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Apr 5, 2024 11:21 PM CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy

Apr 5, 2024 06:31 AM Johnson & Johnson to Acquire Shockwave Medical

Apr 4, 2024 06:01 PM Johnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment Corporation

Apr 2, 2024 04:30 PM Johnson & Johnson to Participate in the BofA Securities Health Care Conference

Mar 25, 2024 08:00 AM Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE™ Platform for the Treatment of Paroxysmal Atrial Fibrillation

Mar 12, 2024 09:15 AM Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

Mar 11, 2024 04:30 PM Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Mar 7, 2024 08:33 AM Johnson & Johnson Completes Acquisition of Ambrx

Mar 1, 2024 03:59 PM RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutat

Feb 20, 2024 04:26 PM TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma

Feb 14, 2024 04:30 PM Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference

Feb 12, 2024 04:10 PM Johnson & Johnson to Participate in the Leerink Global Biopharma Conference

Feb 2, 2024 07:38 PM Biosense Webster Presents Late-Breaking Data from inspIRE and admIRE Clinical Trials at AF Symposium

Feb 2, 2024 04:10 PM Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference

Jan 23, 2024 06:20 AM Johnson & Johnson Reports Q4 and Full-Year 2023 Results

Jan 9, 2024 08:00 AM Biosense Webster Announces Regulatory Approval of VARIPULSE™ Pulsed Field Ablation (PFA) Platform in Japan

Jan 8, 2024 07:30 AM Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer

Jan 2, 2024 08:00 AM Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024

Dec 13, 2023 09:21 AM Key Talc Lawyers: Planned “Prepack” J&J Bankruptcy is “Farce” and Improper Litigation Tactic

Dec 11, 2023 04:15 PM Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

Dec 7, 2023 04:15 PM Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 5, 2023 10:42 AM Publication in Bloomberg Law: ‘A Third J&J Bankruptcy Attempt Won’t Resolve Victims’ Talc Claims’ by Andy Birchfield

Dec 5, 2023 07:15 AM Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review

Nov 30, 2023 04:30 PM Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors

Nov 30, 2023 08:40 AM Johnson & Johnson MedTech Acquires Laminar, Inc.

Nov 17, 2023 12:05 PM Talc Lawyer: Johnson & Johnson Settlements Undermine Bankruptcy Strategy, Serve as Acknowledgment That Baby Powder Contained Asbestos

Nov 16, 2023 07:30 AM Johnson & Johnson to Host Enterprise Business Review

Nov 2, 2023 07:18 PM Key Lawyer in Johnson & Johnson Talc Litigation Supports Call to Rethink Legal Strategies in Light of Failure of Texas Two-Step

Nov 2, 2023 08:00 AM New Biosense Webster QDOT MICRO™ Catheter Data Demonstrate Very High-Power, Short-Duration Ablations Improved Quality of Life and Reduced Healthcare Utilization for AFib Patients

Oct 30, 2023 12:42 PM Cancer Victims Support Sen. Richard Blumenthal in Urging Johnson & Johnson to Accept Responsibility

Oct 23, 2023 04:15 PM Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech

Oct 19, 2023 01:43 PM Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2023

Oct 17, 2023 06:20 AM Johnson & Johnson Reports Q3 2023 Results

Oct 3, 2023 01:00 AM Press Release Biocartis Group NV: Disclosure of transparency notification

Sep 18, 2023 04:30 PM Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results

Sep 14, 2023 10:00 AM Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity

Sep 6, 2023 07:00 AM MustGrow and Janssen PMP, a division of Janssen Pharmaceutica NV, Announce Significant Project Expansion

Aug 30, 2023 06:30 AM Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation

Aug 23, 2023 06:20 AM Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc.

Aug 22, 2023 10:24 AM Johnson & Johnson to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 21, 2023 06:01 PM Kenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600

Aug 21, 2023 06:20 AM Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer

Aug 16, 2023 06:52 PM Johnson & Johnson Announces Final Exchange Ratio of 8.0324 in Split-Off of Kenvue Inc.

Aug 9, 2023 06:42 PM Kenvue Set to Join S&P 500

Aug 7, 2023 07:29 PM Johnson & Johnson to Participate in the 2023 Wells Fargo Securities Healthcare Conference